Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,406.21
(
0.99%
)
US TECH 100
22,699.20
(
1.65%
)
Dow Jones
45,505.64
(
0.64%
)
Brent Oil
107.53
(
-0.96%
)
Bitcoin
66,484.11
(
-0.33%
)
News Focus
News Focus
Post# of 257318
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: GrthzGd post# 140450

Thursday, 04/19/2012 10:10:09 AM

Thursday, April 19, 2012 10:10:09 AM

Post# of 257318

Achillion is at a disadvantage to its competitors because none of its HCV drugs in development are nucleosides.



http://seekingalpha.com/article/320708-achillion-s-hepatitis-c-pipeline-is-a-longshot


i am just following the price action, the science specifics are above my paygrade,lol
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today